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Background. Mass drug administration (MDA) may further reduce malaria transmission in low-transmission areas. The impact 
of MDA on the dynamics of malaria transmission was determined in a prospective cohort study.
Methods. Annual rounds of MDA with dihydroartemisinin-piperaquine (DP) were implemented were implemented in 2014 
and 2015 in six village pairs before the malaria transmission season. Blood samples were collected from residents between July and 
December for microscopy and nested PCR. Incidence and prevalence of infection, clinical disease, and risk of malaria reinfection 
post-MDA were determined.
Results. Coverage of three DP doses was 68.2% (2014) and 65.6% (2015), compliance was greater than 80%. Incidence of infection 
was significantly lower in 2014 (incidence rate [IR] = 0.2 per person year [PPY]) than in 2013 (IR = 1.1 PPY; P < .01); monthly infection 
prevalence declined in the first three months post-MDA. Clinical malaria incidence was lower in 2014 (IR = 0.1 PPY) and 2015 (IR = 0.2 
PPY) than in 2013 (IR = 0.4 PPY; P < .01), but remained higher in eastern Gambia. Individuals infected before MDA had a 2-fold higher 
odds of reinfection post-MDA (adjusted odds ratio = 2.5, 95% confidence interval 1.5–4.3; P < .01).
Conclusions. MDA reduced malaria infection and clinical disease during the first months. The reduction was maintained in 
low-transmission areas, but not in eastern Gambia. Annual MDA could be followed by focal MDA targeting individuals infected 
during the dry season. Repeated MDA rounds, some during the dry season over larger geographical areas, may result in a more 
marked and sustained decrease of malaria transmission.
Keywords. dihydroartemisinin-piperaquine; mass drug administration; malaria infection; clinical malaria; gametocytes.
Malaria causes approximately 216 million cases and 445 000 deaths 
annually, most of them in Sub-Saharan Africa. Plasmodium falcip-
arum is the main species [1], with the other species representing less 
than 5% of infections in Western Africa [2, 3]. Malaria has decreased 
over the last decades worldwide, including in The Gambia [4], 
where its transmission has become heterogeneous, with infection 
prevalence of 10–40% in the east and <5% in the west [5–8].
The World Health Organization (WHO) recommends mass 
drug administration (MDA), which is a full course of an antimalar-
ial treatment to the whole population [9, 10], for areas approaching 
malaria elimination [9, 11]. Successful campaigns, besides treat-
ment efficacy, depend on high coverage and good compliance [12]. 
MDA with an artemisinin-based combination treatment (ACT) 
reduces transmission by clearing asexual infections and ear-
ly-stage gametocytes in asymptomatic, infected individuals [11]. 
Dihydroartemisinin-piperaquine (DP) is used for MDA because of 
its simple dosing schedule, long post-treatment prophylaxis period 
[13–15], and good safety profile [16]. Recent reviews on DP safety 
[17] did not confirm earlier reports of increases and prolongation 
of the QTc interval within 48 hours [14, 18].
The objectives of this study were to describe the malaria 
transmission dynamics of following a yearly MDA round with 
DP for 2 consecutive years, and to determine the risk of malaria 
reinfection after each MDA round.
METHODS
Study Sites and Follow-up
Malaria transmission in The Gambia is seasonal (July-
December), with little transmission during the dry season 
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(January-June). In 2013, a cohort including all residents was set 
up in 6 pairs of villages, in 6 regions: the West Coast Region, 
North Bank Region, Lower River Region, Central River Region, 
and Upper River Region, which was divided into the north 
(URR-N) and south (URR-S) regions. Villages in each pair were 
1–3 km apart and close to the Senegalese border (Figure  1). 
Residents were predominantly farmers.
Residents who provided written, informed consent were 
enrolled in May 2013 and included in monthly surveys during 
3 transmission seasons (2013–2015 from June–December). 
An additional survey was done during the dry season in both 
2014 and 2015. Information on malaria symptoms, treat-
ment, and risk factors was collected, as well as a finger-prick 
blood sample for haemoglobin measurement, thick blood 
smears, and dried blood spots (Whatman 3 Corporation, 
Florham Park, NJ). Clinical malaria cases were identified 
by passive detection at health facilities. Participants with 
histories of fever in the previous 24 hours and/or an axil-
lary temperature greater than 37.5°C had a rapid diagnostic 
test (Paracheck Pf, Orchid Biomedical System, India), and 
positives were treated with artemether-lumefantrine. Mean 
monthly rainfall data were collected from regional meteo-
rology stations.
Mass Drug Administration With Dihydroartemisinin-Piperaquine 
In 2014 and 2015, MDA with DP was implemented over 6 
to 14 days in June and May, respectively, across all study vil-
lages. DP was administered to participants aged 6 months to 
75 years old with a body weight ≥5 kg and no known history 
of cardiac or renal disease. Women aged 11–45  years were 
offered a urine human chorionic gonadotropin pregnancy 
test; positive women were excluded and referred to antenatal 
care clinics for intermittent preventive treatment. Residents 
who returned from travel after the MDA did not receive DP 
(Figure 2).
Treatment Administration
DP (Eurartesim, Sigma-Tau, Industrie Farmaceutiche Riunite, 
Italy) administration, according to weight-based dosing guide-
lines, was directly observed by 5 field research teams that were 
working with government nurses and village health workers.
Safety Profile
Adverse events (AEs) were monitored passively for 28  days. 
Relatedness of AEs to the intervention was based on known DP 
side effects and the timing after treatment. AEs were graded by 
severity, as mild, moderate, or severe.
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Figure 1. Study sites and monthly malaria prevalence and incidence of infection by region, before (2013) and after (2014) 1 annual MDA round. Abbreviations: DP, dihy-
droartemisinin-piperaquine; IR, incidence rate; MDA, mass drug administration; PPY, per person, per year.
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Molecular Diagnostics and Parasitology
P.  falciparum was detected by nested polymerase chain re-
action (PCR) from the blood-spot samples collected in the 
2014  monthly surveys. Briefly, DNA was extracted using an 
automated QIAxtractor robot (Qiagen) and 4 µl was used in a 
nested PCR [19]. All PCR products were run with the QIAxcel 
capillary electrophoresis system (Qiagen), using the screening 
cartridge and 15–1000 bp-alignment markers. Results were 
exported and double scored using both the QIAxcel binary 
scoring function and manually, by visualization of the gel 
images; discrepancies were scored by a third reader.
Thick smears from all the positive, nested PCR samples and 
clinical malaria cases (n = 1480) were read by 2 independent 
microscopists, and discrepancies were settled by a third reader. 
Parasite density was estimated by the number of parasites per 
200 white blood cells, assuming 8000 white blood cells per μL. 
Blood smears were considered negative after reading 100 high-
power fields.
Consent
Verbal approval was obtained at village sensitization meetings 
in May–April of 2013–2015 and 2 weeks prior to the MDA. 
Information sheets were given to all study participants. Written, 
individual consent was obtained from literate adults; parents 
or guardians consented for children <12  years, and children 
12–18 years provided written assent. The study was approved 
by the Gambia Government/Medical Research Council Ethics 
Committee (SCC 1318). The approval to import DP was 
obtained from the Gambian Medicine Control Agency.
Data Management
Data were captured using case report forms and were verified 
for internal consistency by the field coordinators. Data were 
double entered using the SQL program version 36, and were 
verified and cleaned.
Study Outcomes
The primary outcome was malaria (P.  falciparum) infection, 
determined by nested PCR. Secondary outcomes included DP 
coverage and compliance; the incidence of clinical malaria; the 
prevalence of gametocytaemia; asymptomatic and sub-patent 
infections; and AEs. Asymptomatic malaria was defined as an 
infection, determined by nested PCR, in an afebrile individual 
with no history of fever in the previous 24 hours [20]. Clinical 
malaria was defined as a positive microscopy or rapid diagnos-
tic test (RDT) with a history of fever or a temperature >37.5°C 
[15]. Sub-patent infections were defined as infections that were 
positive by nested PCR and negative by microscopy.
Statistical Analysis
The incidence rates of infection and clinical malaria were cal-
culated as the number of infections or clinical cases, divided by 
the total person-time at risk (per person, per year). The prev-
alence of asymptomatic infection was calculated as the num-
ber of infections, divided by the number of individuals with 
no history of fever. DP coverage was calculated as the number 
of treated individuals who received 3 DP doses, divided by the 
village population. Compliance was calculated as the propor-
tion of eligible individuals who had full treatment. Gametocyte 
June 2014  N = 4311 May 2015  N = 4189
Not Screened = 586 (13.6%)
• Travel/farm/herder = 392 (66.9)
• Refusals = 173 (29.5%)
• Other = 21 (3.6%)
Screened n = 3725 (86.4%)
Excluded N = 185 (4.9)
• Pregnant = 132
• Elderly (≥75 years) = 52
• Infants ≤ 5kgs = 1
1 dose
n = 203 (5.7%)
2 doses
n = 395 (11.2)
3 doses 
n = 2942 (83.1%)
Not Screened = 815(19.5%)
• Travel/farm/herders = 470 (57.7%)
• Refusals = 259 (31.8%)
• Other = 86 (10.6%)
Screened n = 3374 (80.5)
Excluded: N = 176 (5.2%)
• Pregnant = 112
• Elderly (≥75 years) = 64
• Infants ≤5 kgs = 0
3 doses 
n = 2748 (85.9%)
1 dose 
n = 117 (3.7%)
2 doses 
n = 333 (10.4%)
Figure 2. Study flow diagram.
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prevalence was calculated as the number of individuals with 
gametocytes, divided by the total number of infected individu-
als, as determined by microscopy.
The risk ratio of infections and incidence rate ratio of clinical 
malaria, before and after MDA, were estimated by comparing the 
prevalences and incidences in April 2014 and in July–December 
2014, as well as in the 2013 transmission season and in the 2014 
and 2015 transmission seasons. DP efficacy was determined in 
2014 for the treated individuals that were sampled between days 
14 to 28 and around day 42. For participants infected in the dry 
season (April), logistic regression models were fitted to determine 
the odds of infections at 4 weeks and around day 42 post-MDA. 
The protective efficacy for clinical malaria was determined for 
2014 and 2015 post-MDA using a mixed-effects logistic regres-
sion model, and accounting for clustering at the regional level. 
Multivariable models were adjusted for age, gender, long lasting 
insecticide treated net (LLIN) use, sleeping outdoors, and travel 
history. Analyses were performed using Stata version 13.0 [21].
RESULTS
A total of 4312 and 4189 individuals were followed in 2014 and 
2015, respectively. The median age was 13 years (interquartile 
range: 5, 28). LLIN use the previous night was lower each year 
in April (2014: 43.3%, 1374/3171; 2015: 51.8%, 1545/2982), 
but increased substantially during and after the rainy seasons; 
the overall use was 87.8% (3072/3501) in 2014 and 77.9% 
(2940/3771) in 2015. Few residents traveled: 4.8% (202/4189) in 
2014 and 3.9% (149/3738) in 2015, with a median of 22 (inter-
quartile range: 12, 31) days absence (Table 1).
 Screening for MDA was done for 86.4% (3725/4312) and 80.5% 
(3374/4189) of potential participants in 2014 and 2015, respec-
tively; 5% of them were non-eligible, mainly because of pregnancy 
(Figure 2). In 2014, 586 individuals did not participate, because 
they were absent (66.9%, 392/586) or refused (29.5% (173/586). In 
2015, 57.7% (470/815) were away and (13.8%, 259/815) refused. 
Compliance to 3 DP doses was 83.1% (2942/3540) in 2014 and 
85.9% (2748/3198) in 2015 (Figure 2). Coverage of the 3 doses was 
68.2% (2942/4312) in 2014 and 65.6% (2748/4189) in 2015.
After MDA, the monthly infection prevalence was sig-
nificantly lower during the whole 2014 transmission season, 
as compared to 2013 (2014: 5.9%, 1307/22 036; 2013: 8.7%, 
1796/20 552; risk ratio [RR] = 0.7; P < .01). Malaria prevalence 
was significantly lower in the 3 months following MDA—that 
is, in July (5.9%, 188/3150; RR = 0.8; P =  .02), August (4.7%, 
160/3411; RR = 0.6; P <  .01), and September (1.9%, 60/3252; 
RR = 0.3; P < .01)—than in April 2014 (7.5%, 213/2827; Table 2).
In 2014, across all regions, the incidences of infection were 
significantly lower than in 2013 (Supplementary Table  1 and 
Figure 1). Malaria prevalence remained significantly higher in 
the URR-S (355/5208, 6.8%) and URR-N (244/2342, 10.4%) 
than in the West Coast Region (P  <  .01; Supplementary 
Table 2). In 2014, the largest reduction in malaria prevalence 
was in eastern Gambia. In November, the time of peak trans-
mission, asymptomatic malaria prevalence was lower in 2014 
than in 2013; it decreased by 50% or more in the URR-S (65.2% 
reduction; 2013 = 13.6%, 92/679, versus 2014 = 4.7%, 31/658; 
RR  =  0.05; P  <  .01), URR-N (57.9%; 2013  =  36.4%, 122/335 
versus 2014  =  15.3%, 53/346, RR  =  0.2; P  <  .01), and Lower 
River Region (49.7% reduction; 2013  =  8.9%, 39/436 versus 
2014 = 4.5%, 15/333; RR = 0.5; P = .001).
More than half of all infections were sub-patent in 2014 
(April: 55.1%, 92/167; July: 50%, 65/129; August: 50.4%, 65/129; 
September: 68.3%, 41/60; October: 58.1%, 118/203; November: 
56.3%, 126/224; December: 68%, 41/60). The overall gameto-
cyte carriage during the 2014 transmission season was 8.3% 
(46/552), and was lower in August (2/70, 2.9%) than in April 
(8/87, 9.2%; Supplementary Table 3). Median P. falciparum den-
sities were significantly lower in the 2014 transmission season, 
as compared to the 2013 season, in all regions but the URR-N 
(Figure 3). Before MDA, 1 P. malariae infection was detected in 
2014 and 7 P. ovale infections were detected in 2013.
In 2014, the malaria prevalence between 14–28  days and 
42 days post-MDA was 5.5% (131/2432) and 4.2% (147/3534), 
Table 1. Study Subjects Characteristics
Characteristic 2014, n (%) 2015, n (%)
Gender
 Male 1966 (46.1) 1932 (46.1)
 Female 2296 (53.9) 2256 (53.9)
Age category
 ≤5 years 1091 (25.6) 1054 (25.2)
 6–15 years 1336 (31.4) 1433 (34.2)
 ≥16 years 1830 (42.9) 1702 (40.6)
Long lasting insecticide-treated  
net use previous night
 April 1374/3171 (43.3) 1545/2982 (51.8)
 Junea - 2201/3106 (70.9)
 July 2222/3318 (66.9) 2011/2984 (67.4)
 August 3184/3542 (89.9) 2599.3024 (85.9)
 September 3122/3281 (95.2) 2769/2938 (94.3)
 October 3146/3310 (95.1) 2808/2950 (95.2)
 November 3003/3163 (94.9) 2532/2800 (90.4)
 December 2879/3191 (90.2) 2112/2806 (75.3)
Travelled in the last month
 April 251/3161 (7.9) 218/2956 (7.4)
 May 228/3079 (7.4)
 July 277/3287 (8.4) 40/2966 (1.4)
 August 86/3500 (2.5) 31/3008 (1.0)
 September 126/3255 (3.9) 37/2921(1.3)
 October 95/3279 (2.9) 69/2925 (2.4)
 November 59/3133 (1.9) 26/27 770 (1.3)
 December 52/3170 (1.6) 39/2796 (1.4)
House structure (n = 2233) 2111 (75.3)
 Traditional house 1182 (52.9)
 Modern house 1051 (47.1)
aNo survey was conducted in June 2014 before the mass drug administration campaign.
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respectively, with half of the infections (49.6%, 65/131) sub-pat-
ent. MDA decreased the risk of being infected, but the differ-
ence between treated and untreated individuals was statistically 
significant only for those who had received the 3-day treatment, 
both in July (adjusted odds ratio [AOR] 0.6, 95% confidence 
interval [CI] 0.4–1.0; P =  .04) and August (AOR 0.5, 95% CI 
0.3–0.9; P = .02; Table 3).
The odds of clinical malaria in July 2014 were significantly 
lower among subjects who took 3 DP doses (AOR 0.3, 95% CI 
0.1–0.9; P = .02), as compared to untreated individuals. At 3–4 
weeks post-MDA 2014, 19 (8.92%) individuals among the 213 
infected in April were still infected: 10 had received the full 
3-day treatment, such that more than half (52.6%, 10/19) were 
patent infections.
The efficacy of MDA in clearing and preventing infections was 
assessed in 2276 individuals who received full treatment and had 
a known infection status in both July and August 2014. Among 
the 113 individuals infected in July 2014, 89.4% (101/113) had 
cleared the infection by August; only 82 (3.8%) among the 2163 
individuals not infected in July became infected in August.
Individuals infected in the dry season (2014) had 2-fold 
higher odds of being infected in July (AOR  2.5, 95% CI 
Table 2. Malaria Prevalence by Month and Year; Risk Ratio of Infection by Month
Month 2013 Prevalence (n/N) 2014 Prevalence (n/N)
RR 2013 vs 2014 by 
month (95% CI) P Value
RR April 2014 vs Other 
Months 2014 (95% CI)  P Value
April NA 7.5 (213/2827) 1
June 5.3 (75/1409) NA NA
July 5.3 (180/3411) 5.9 (188/3150) 1.1 (0.9–1.4) .2 0.8 (0.7–0.9) .02
August 6.2 (195/3133) 4.7 (160/3411) 0.8 (0.6–0.9)  .01 0.6 (0.5–0.8)  <.01
September 5.1 (146/2867) 1.8 (60/3252) 0.4 (0.3–0.5)  <.01 0.24 (0.2–0.3)  <.01
October 11.2 (347/3113) 6.7 (210/3156) 0.6 (0.5–0.7)  <.01 0.9 (0.7–1.1)  .2
November 14.4 (503/3492) 7.6 (247/3240) 0.6 (0.5–0.7)  <.01 1.0 (0.9–1.2) .9
December 11.2 (350/3127) 7.6 (229/3000) 0.7 (0.6–0.8)  <.01 1.0 (0.8–1.2) .9
Total 8.7 (1796/20 552) 5.9 (1307/22 036) 0.7 (0.65–0.8) <.01
 Abbreviations: CI, confidence interval; NA, not available; RR, risk ratio. 
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Figure 3. Monthly prevalence and density of Plasmodium falciparum infections, before and after 1 MDA round. Abbreviations: DP, dihydroartemisinin-piperaquine; MDA, 
mass drug administration.
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1.5–4.3; P < .01), August (AOR 2.8, 95% CI 1.6–5.1; P = .001), or 
throughout the transmission season (AOR 2.5, 95% CI 1.7–3.6; 
P < .01; Supplementary Table 4).
The odds of clinical malaria were significantly lower in 2014 
(AOR 0.4, 95% CI 0.3–0.6; P < .01) and 2015 (AOR 0.6, 95% CI 
0.5–0.7; P < .01) in those fully treated, as compared to untreated 
individuals (Table 4). The incidence of clinical malaria was sig-
nificantly lower in all regions after the first and second MDA, as 
compared to 2013 (Supplementary Table 5). The incidence of clin-
ical malaria was similar after the first and second MDA rounds, 
except in the URR-S and URR-N, where the incidence was signif-
icantly higher in 2015 than in 2014 (Figure 4 and Supplementary 
Table  5). In the URR-S and URR-N, the rainfalls lasted longer 
(May-December) in 2015 than in 2013 and 2014 (Figure 4).
Dihydroartemesinin-Piperaquine Safety
Within the 28 days post-MDA, 302 and 269 AEs were reported 
in 2014 and 2015, respectively, with similar proportions of symp-
toms in both years. The most common AEs were headache 
(2014: 18.9%, 57/302; 2015: 18.2%, 49/269), fever (2014: 12.6%, 
38/302; 2015:  11.5%, 31/269), malaise (2014:  11.9%, 36/302; 
2015:  12.6%, 34/269), and vomiting (2014:  11.3%, 34/302; 
2015: 10.0%, 27/269). AEs were either mild or moderate in sever-
ity and were all probably related to DP, except for fever and chills 
(Supplementary Table 6). No serious adverse events were detected.
DISCUSSION
We assessed the impact of an annual round of MDA with DP, 
an ACT with a long post-treatment prophylactic period, on ma-
laria transmission dynamics over 2 consecutive years in areas of 
differing transmission intensity in The Gambia [8].
The prevalence and incidence of infection in 2014 were sig-
nificantly lower than in 2013, but remained significantly higher 
in eastern Gambia, as compared to other regions. The monthly 
prevalence, after a significant decrease in the first 3  months 
post-MDA, returned to similar pre-MDA levels. Clinical ma-
laria decreased in both intervention years, but remained signif-
icantly higher in eastern Gambia, increasing in the second year 
as compared to the first, and confirming the higher transmission 
Table 3. Risk Factors of Malaria Infection 14–28 Days (July 2014) and 42 
Days (August 2014) After mass drug administration
Day 14–28 Day 42
AOR (95% 
CI)a P Value
AOR (95% 
CI)a P Value
MDA DP
 No treatment 1 1
 1–2 doses 0.7 (0.4–1.3)  .3 0.6 (0.3–1.2)  .1
 3 doses 0.6 (0.4–1.0)  .04 0.5 (0.3–0.9)  .02
Age group
 ≤5 years 1 1
 6–17 years 1.2 (0.8–1.9)  .4 1.2 (0.8–1.8)  .3
 ≥18 years 0.9 (0.5–1.4)  .5 0.9 (0.6–1.4)  .4
Long lasting insecti-
cide-treated net use 
previous night
  No 1 1
  Yes 1.4 (0.9–1.9)  .08 1.0 (0.6–1.4)  .8
Gender
 Male 1
 Female 0.8 (0.6–1.1)  .2
Study site
 WCR 1
 NBR 1.2 (0.6–2.3)  .6
 LRR 1.7 (0.9–3.2)  .12
 CRR 0.9 (0.4–1.9) .8
 URR-S 1.0 (0.52–1.74)  .9
 URR-N 4.9 (2.8–9.0) <.01
Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; CRR, Central River 
Region; DP, dihydroartemisinin-piperaquine; LRR, Lower River Region; MDA, mass drug 
administration; NBR, North Bank Region; URR-N, Upper River Region, north; URR-S, Upper 
River Region, south; WCR, West Coast Region.
aVariables with P values  <  .1 in the univariate analysis (gender and study sites) or that 
were confounders (long lasting insecticide-treated net use at night and age groups) were 
included in the multivariate analysis. Variables with P values  >  .1 in univariate analysis 
(sleeping outside and travel history) were excluded in the multivariate analysis.
Table 4. Risk Factors of Clinical Malaria Post-Mass Drug Administration 
by Year
2014 Transmission 
Season
2015 Transmission 
Season
AOR
(95% CI) P Value
AOR
(95% CI) P Value
MDA DP
 No treatment 1 1
 1–2 doses 0.7 (0.4–1.4)  .4 0.7 (0.5–1.0) .05
 3 doses 0.4 (0.3–0.6)  <.01 0.59 (0.5–0.7)  <.01
Age group
 ≤5 years 1 1
 6–17 years 0.8 (0.5–1.2) .3 1.2 (0.9–1.6)  .1
 ≥18 years 0.5 (0.3–0.8)  .003 0.9 (0.7–1.2)  .5
Gender
 Male 1 1
 Female 0.7 (0.5–0.9) .02 0.8 (0.6–0.9)  .02
Long lasting insecticide 
treated-net use pre-
vious night
 No 1 1
 Yes 0.5 (0.3–0.7)  <.01 0.71 (0.5–0.9)  .02
Travelled
 No 1
 Yes 0.7 (0.3–1.9)  .5 1.9 (1.7–2.1)  <.01
Month
 April 1 1
 June 0.5 (0.1–0.5) .6 0.4 (0.1–1.8) .2
 July 0.1 (0.02–0.6) .01 0.3 (0.1–1.2) .1
 August 0.5 (0.1–1.5) .2 1.3 (0.5–3.2) .61
 September 0.8 (0.4–2.4) .7 4.5 (2.03–9.9) <.01
 October 3.2 (1.3–7.9) .01 16.8 (7.9–35.7) <.01
 November 12.7 (5.5–9.2) <.01 26.2 (12.5–54.7) <.01
 December 1.1 (0.5–2.9) .8 5.4 (2.5–11.5) <.01
Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; DP, dihydroartemisi-
nin-piperaquine; MDA, mass drug administration.
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intensity in this region [8, 22]. The administration of 1 annual 
MDA round over 2 consecutive years resulted in a temporal de-
cline of malaria infections and clinical disease, with a temporal 
shift and decrease in the peak prevalence and incidence of in-
fection and clinical disease. In The Gambia, MDA with sulfa-
doxine-pyrimethamine and a single artesunate dose resulted in a 
lower incidence of clinical malaria for 2 months following MDA 
[10]. In Zambia, 2 MDA rounds showed a lower prevalence for 
at least 6 months in the low-transmission sites [11]. In Myanmar, 
MDA with DP and a single low dose of primaquine significantly 
reduced P.  falciparum prevalence 3  months after MDA in in-
tervention villages, as compared to controls [19]. Therefore, 
although WHO currently recommends MDA where transmis-
sion is low, such recommendations could be extended to mod-
erate-transmission areas, given the substantial but time-limited 
decrease in prevalence and incidence we observed. Multiple 
MDA rounds could result in a larger and more sustained re-
duction [23], particularly if appropriately timed; for example, a 
round during the dry season could decrease the human reservoir 
before transmission begins. In addition, DP could be combined 
with invermectin, which would reduce mosquito survival [24].
Here, 1 annual MDA round was unable to maintain the 
observed malaria decline throughout the transmission season. 
Nevertheless, the incidence of clinical malaria in the western and 
central regions remained low across the 2 intervention years, 
while in eastern Gambia we observed an increase during the 
second year, probably due to environmental factors, such as the 
longer duration of rainfall, which resulted in higher mosquito 
density and survival. Therefore, in low-transmission areas, such 
as western and central Gambia, 1 appropriately-timed annual 
MDA round could reduce the clinical case burden on the health-
care system and maintain this effect over time if implemented 
regularly. Cost-benefit comparisons between this approach and 
clinical case management are needed to confirm this potential 
value. As the intervention was implemented in 2 villages in each 
region, transmission may have been maintained by population 
movements [25–27]. Increasing the size of the intervention area, 
extending the duration of campaigns, and ensuring individuals 
who missed MDA are prioritized in additional rounds would 
achieve a larger effect [23]. Since transmission intensity varied 
substantially by year and there were no control villages, it is not 
possible to quantify the MDA’s additional (to standard control 
interventions) impact on malaria transmission.
MDA coverage was relatively high and was comparable 
to previous studies, which had coverage rates of 85% in The 
Gambia [28], >95% in Tanzania [29], 72–88% in Zambia [30], 
and 28–61% in Myanmar [31]. Villages where coverage was 
below 70% had high proportions of people traveling or refusing 
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Figure 4. Monthly incidence of clinical malaria by region, before (2013) and after (2014) 1 annual MDA round. Abbreviations: DP, dihydroartemisinin-piperaquine; IR, inci-
dence rate; MDA, mass drug administration; PPY, per person year.
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treatment, despite meetings and mobilization campaigns, high-
lighting the main challenges for MDA implementation [32, 33]. 
Compliance was high, as doses were directly observed, but may 
be lower in programmatic conditions [34].
In both intervention years, full DP treatment significantly 
reduced the risk of clinical malaria throughout the transmis-
sion season. This is due to the excellent DP efficacy and long 
post-treatment prophylaxis, related to the long elimination 
half-life of piperaquine (20  days in children and 22  days in 
adults) [9, 12–14, 16]. Incomplete treatment was not protective, 
probably due to the shortened post-treatment prophylaxis [35]. 
It is not possible to determine whether infections observed at 
days 28–42 were residual or new infections, as no genotyping 
was done. About half of them were detectable only by molec-
ular methods. Low-density infection is common following 
ACT treatment: 31.8% of children treated with an ACT had re-
sidual parasitaemia, as detected by quantitative PCR, at day 3 
post-treatment [36], while 25% of patients treated with an ACT 
had parasitaemia at day 14, as detected by quantitative  real-
time PCR [37]. Therefore, a substantial proportion of infections 
detected after MDA may be residual, and not new infections.
Individuals infected in April 2014 had a significantly higher 
risk of infection during the transmission season. Such risk is 
probably due to higher exposure—for example, close proximity 
to breeding sites or an environment favoring exposure to the 
vector—and not to residual parasitaemia or gametocytaemia, as 
the latter would decrease after 2 months [38, 39]. This suggests 
that the risk of infection and clinical disease is extremely focal, 
as already shown in The Gambia [8], Senegal [40], and Kenya 
[41]. Besides treating the whole population, households with 
infected individuals at the beginning of the transmission season 
could be targetted with focal MDA [30].
The RDT for the diagnosis of clinical malaria, the Paracheck 
Pf, did not perform well at low parasite densities (200/µl) during 
the last WHO evaluation round  [42]. This RDT was used only 
to diagnose clinical malaria cases, which have higher parasite 
densities. Therefore, considering that Paracheck Pf had a high 
panel-detection score at parasite densities of 2000/µl, it is un-
likely that clinical malaria cases would have gone undiagnosed.
CONCLUSIONS
Annual MDA with DP reduced the prevalence and incidence of 
infection and clinical disease in the first months of each trans-
mission season. In western and central Gambia, where trans-
mission is low, the clinical malaria incidence was reduced over 
2  years, despite an apparent higher transmission during the 
second year. In future, 1 MDA round could be followed by a 
MDA targeting those households with individuals identified as 
infected during the dry season. Repeated MDA rounds, some of 
them during the dry season and over a much larger geograph-
ical area, may result in a more marked and sustained decrease 
of malaria transmission.
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